Cited by 610Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Open access

Paz-Ares, Luis, de Marinis, Filippo, Dediu, Mircea, Thomas, Michael, Pujol, Jean-Louis, Bidoli, Paolo, Molinier, Olivier, Sahoo, Tarini Prasad, Laack, Eckart, Reck, Martin, Corral, Jesús, Melemed, Symantha, John, William, Chouaki, Nadia, Zimmermann, Annamaria H, Visseren-Grul, Carla, Gridelli, Cesare·2012·The Lancet Oncology

DOI 10.1016/s1470-2045(12)70063-3

Open this paper in CoChat — free account

Abstract

Background Patients with advanced non-squamous non-small-cell lung cancer (NSCLC) benefit from pemetrexed maintenance therapy after induction therapy with a platinum-containing, non-pemetrexed doublet. The PARAMOUNT trial investigated whether continuation maintenance with pemetrexed improved progression-free survival after induction therapy with pemetrexed plus cisplatin.Methods In this double-blind, multicentre, phase 3, randomised placebo-controlled trial, patients with advanced non-squamous NSCLC aged 18 years or older, with no previous systemic chemotherapy for lung cancer, with at least one measurable lesion, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 participated. Before randomisation, patients entered an induction phase which consisted of four cycles of induction pemetrexed (500 mg/m(2)) plus cisplatin (75 mg/m(2)) on day 1 of a 21-day cycle. Patients who did not progress after completion of four cycles of induction and who had an ECOG performance status of 0 or 1 were stratified according to disease stage (IIIB or IV), ECOG performance status (0 or 1), and induction response (complete or partial response, or stable disease), and randomly assigned (2:1 ratio) to receive maintenance therapy with either pemetrexed (500 mg/m(2) every 21 days) plus best supportive care or placebo plus best supportive care until disease progression. Randomisation was done with the Pocock and Simon minimisation method. Patients and investigators were masked to treatment assignment. The primary endpoint was progression-free survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT00789373.Findings Of the 1022 patients enrolled, 939 participated in the induction phase. Of these, 539 patients were randomly assigned to receive continuation maintenance with pemetrexed plus best supportive care (n=359) or with placebo plus best supportive care (n=180). Among the 359 patients randomised to continuation maintenance with pemetrexed, there was a significant reduction in the risk of disease progression over the placebo group (HR 0·62, 95% CI 0·49-0·79; p<0·0001). The median progression-free survival, measured from randomisation, was 4·1 months (95% CI 3·2-4·6) for pemetrexed and 2·8 months (2·6-3·1) for placebo. Possibly treatment-related laboratory grade 3-4 adverse events were more common in the pemetrexed group (33 [9%] of 359 patients) than in the placebo group (one [<1%] of 180 patients; p<0·0001), as were non-laboratory grade 3-5 adverse events (32 [9%] of 359 patients in the pemetrexed group; eight [4%] of 180 patients in the placebo group; p=0·080); one possibly treatment-related death was reported in each group. The most common adverse events of grade 3-4 in the pemetrexed group were anaemia (16 [4%] of 359 patients), neutropenia (13 [4%]), and fatigue (15 [4%]). In the placebo group, these adverse events were less common: anaemia (one [<1%] of 180 patients), neutropenia (none), and fatigue (one <1%]). The most frequent serious adverse events were anaemia (eight [2%] of 359 patients in the pemetrexed group vs none in the placebo group) and febrile neutropenia (five [1%] vs none). Discontinuations due to drug-related adverse events occurred in 19 (5%) patients in the pemetrexed group and six (3%) patients in the placebo group.Interpretation Continuation maintenance with pemetrexed is an effective and well tolerated treatment option for patients with advanced non-squamous NSCLC with good performance status who have not progressed after induction therapy with pemetrexed plus cisplatin.Funding Eli Lilly and Company.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(12)70063-3

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
AJCC Cancer Staging Manual
(2016) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,300
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Analysis of Binary Data
Cox, D. R. (2008) · Springer eBooks · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,687
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Self-citation

Show all 33 references

Research works printed but not linked: 1

Ciuleanu, 2008, Impact of induction chemotherapy on the outcome of treatment with pemetrexed in patients with advanced non-small-cell lung cancer: a retrospective analysis of a phase III trial, Ann Oncol, 19, viii98

Sorted by citations

Items 201–300 of 607

Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario
Vega, Y. I. F., González, D. L. P., Sarmiento, S. D. L. C. A., Tul, L. E. A., Valdés, I. B. I., Machado, J. R., Larrinaga, Á. R. E., Rodríguez, J. E. F., García, J. L., Otero, D. C., et al. (2023) · Journal of Cancer · doi:10.7150/jca.67189 · Cited by 17
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
Tan, P. S., Lopes, G. D. L., Jr., Acharyya, S., Bilger, M., & Haaland, B. A. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.007 · Cited by 18
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902
Kim, Y. H., Hirabayashi, M., Togashi, Y., Hirano, K., Tomii, K., Masago, K., Kaneda, T., Yoshimatsu, H., Otsuka, K., Mio, T., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1910-2 · Cited by 17
Maintenance Therapies for Non-Small Cell Lung Cancer
Blais, N., & Kassouf, E. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00213 · Cited by 17
Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study
Li, W., Zhao, X., Wang, H., Liu, X., Zhao, X., Huang, M., Qiu, L., Zhang, W., Chen, Z., Guo, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13922 · Cited by 17
Performance of the neutrophil-to-lymphocyte ratio as a prognostic tool for survival in solid cancers
Carrión-Barberà, I., & Lood, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1616477 · Cited by 16
PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Reck, M., Paz-Ares, L. G., de Marinis, F., Molinier, O., Sahoo, T. P., Laack, E., John, W. J., Zimmermann, A. H., Visseren‐Grul, C., & Gridelli, C. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000076 · Cited by 16
Self-citation
Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer
Durm, G. A., & Hanna, N. H. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.002 · Cited by 16
Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902
Kanazawa, K., Yokouchi, H., Wang, X., Ishida, T., Fujita, Y., Fujiuchi, S., Harada, T., Harada, M., Takamura, K., Oizumi, S., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2589-3 · Cited by 16
Update on the Evidence Regarding Maintenance Therapy
Lee, J. E., & Chung, C. (2014) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2014.76.1.1 · Cited by 17
Effect of renal function on pemetrexed-induced haematotoxicity
Ando, Y., Hayashi, T., Ujita, M., Murai, S., Ohta, H., Ito, K., Yamaguchi, T., Funatsu, M., Ikeda, Y., Imaizumi, K., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3078-7 · Cited by 16
Non-small cell lung cancer
Skřičková, J., Kadlec, B., & Venclíček, O. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.159 · Cited by 16
A Structural Insight Into Two Important ErbB Receptors (EGFR and HER2) and Their Relevance to Non‐Small Cell Lung Cancer
Topalan, E., Büyükgüngör, A., Çiğdem, M., Gura, S. F., Sever, B., Otsuka, M., Fujita, M., DeMirci, H., & Ciftci, H. I. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400992 · Cited by 18
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer
Thomas, M., Fischer, J. R., Andreas, S., Kortsik, C., Grah, C., Serke, M. H., von Eiff, M., Witt, C. C., Kollmeier, J., Müller, E., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00229014 · Cited by 15
Self-citation
Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer
Pérez-Moreno, M. A., Galván-Banqueri, M., Flores‐Moreno, S., Villalba-Moreno, Á. M., Luque, J. C., & Paloma, F. J. B. (2014) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-014-9920-2 · Cited by 15
First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments
Liao, B.-C., Lin, C., & Yang, J. C. (2013) · Drugs · doi:10.1007/s40265-013-0020-8 · Cited by 16
Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901
Kim, Y. H., Hirabayashi, M., Kosaka, S., Nikaidoh, J., Yamamoto, Y., Shimada, M., Toyazaki, T., Nagai, H., Sakamori, Y., & Mishima, M. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2142-9 · Cited by 15
Controversies in the management of stage III non-small-cell lung cancer
Biswas, T., Sharma, N., & Machtay, M. X. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.867809 · Cited by 15
Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment
Nogová, L., Mattonet, C., Scheffler, M., Taubert, M., Gardizi, M., Sos, M. L., Michels, S. Y. F., Fischer, R. N., Limburg, M., Abdulla, D. S. Y., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3131 · Cited by 15
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Gautschi, O. P., Mach, N., Rothschild, S. I., Li, Q., Stahel, R. A., Zippelius, A., Cathomas, R. L., Früh, M., Betticher, D. C., Peters, S., et al. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.02.007 · Cited by 15
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies
Langer, C. J., Paz-Ares, L. G., Wozniak, A. J., Gridelli, C., de Marinis, F., Pujol, J.-L., Antonio, B. S., Chen, J., Liu, J., Oton, A. B., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.003 · Cited by 15
Self-citation
Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model
Moldaver, D., Hurry, M. V., Evans, W. K., Cheema, P. K., Sangha, R. S., Burkes, R. L., Melosky, B. L., Tran, D., Boehm, D., Venkatesh, J., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.019 · Cited by 15
Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study
Petrioli, R., Francini, E., Fiaschi, A. I., Laera, L., Luzzi, L., Paladini, P., Ghiribelli, C., Voltolini, L., Bianco, V., & Roviello, G. (2015) · Medical Oncology · doi:10.1007/s12032-015-0587-x · Cited by 14
NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer
Ettinger, D. S., Kimmel, S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., Jahan, T. M., et al. (2014) · Cited by 14
Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Hu, X., Pu, K., Feng, X., Wen, S., Fu, X. B., Guo, C., & He, W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149247 · Cited by 14
Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001
Okumura, N., Sonobe, M., Okabe, K., Nakamura, H., Kataoka, M., Yamashita, M., Nakata, M., Kataoka, K., Yamashita, Y., Soh, J., et al. (2016) · International Journal of Clinical Oncology · doi:10.1007/s10147-016-1067-9 · Cited by 14
PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed
Zhang, P., Bao, Z., Xu, L., Zhou, J., Lu, G., Yao, Y., Liu, R., Gao, Q., Shen, Y., & Zhou, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19973 · Cited by 14
Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer
Mahmud, F., Jeon, O., Alam, F., Maharjan, R., Choi, J. U., Park, J., Lee, S., Park, J. W., Lee, D. S., & Byun, Y. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.06.018 · Cited by 14
Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer
Lee, V. H.-F., Mok, T. S. K., Goto, Y., Hsue, V. C. C., Li, Y., Jiang, Y., Leung, D. K. C., Lau, K. S., & Tse, P. Y. H. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.07.014 · Cited by 14
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial
Lavolé, A., Greillier, L., Mazières, J., Monnet, I., Kiakouama-Maleka, L., Quantin, X., Spano, J., Léna, H., Fraisse, P., Janicot, H., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02066-2019 · Cited by 14
Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study
Karayama, M., Inui, N., Kuroishi, S., Yokomura, K., Toyoshima, M., Shirai, T., Masuda, M., Yamada, T., Yasuda, K., Suda, T., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2218-6 · Cited by 14
Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
Yokoi, T., Torii, Y., Katashiba, Y., Sugimoto, H., Tanijiri, T., Ogata, M., Inagaki, N., Kibata, K., Hayashi, M., Niki, M., et al. (2014) · Oncology Letters · doi:10.3892/ol.2014.2552 · Cited by 14
Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer
Losanno, T., Rossi, A., Maione, P., Napolitano, A., & Gridelli, C. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1163333 · Cited by 16
Self-citation
Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer
Lund‐Iversen, M., Scott, H., Strøm, E. H., Theiss, N., Brustugun, O. T., & Grønberg, B. H. (2018) · Anticancer Research · doi:10.21873/anticanres.12470 · Cited by 14
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)
Facchinetti, F., Pilotto, S., Metro, G., Baldini, E., Bertolaccini, L., Cappuzzo, F., Delmonte, A., Gasparini, S., Inno, A., Marchetti, A., et al. (2019) · Tumori Journal · doi:10.1177/0300891619857418 · Cited by 14
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial
Spigel, D. R., Jotte, R. M., Ponce-Aix, S., Gressot, L., Morgensztern, D., McCleod, M., Socinski, M. A., Daniel, D. B., Juan, Ó., Mileham, K. F., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.09.007 · Cited by 14
Self-citation
PROFILE 1014: lessons for the new era of lung cancer clinical research.
Noonan, S. A., & Camidge, D. R. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.05.02 · Cited by 14
Thoracic neoplasms
Krzakowski, M. J., Jassem, J., Antczak, A. J., Błasińska, K., Chorostowska‐Wynimko, J., Dziadziuszko, R., Głogowski, M., Grodzki, T., Kowalski, D. R., Krenke, R., et al. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2021.0022 · Cited by 16
Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial
Reynolds, C. H., Spira, A. I., Gluck, L., Mueller, S. E., Feng, Z., Boehm, K. A., & Asmar, L. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9985-0 · Cited by 13
RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine
Chen, Y., Huang, Y., Chen, D., Wu, C., Leng, Q., Wang, W., Deng, M., Zhao, Y., & Yang, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s162667 · Cited by 13
Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting
Winfree, K. B., Torres, A. Z., Zhu, Y. E., Muehlenbein, C. E., Aggarwal, H., Woods, S., & Abernethy, A. P. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1547273 · Cited by 13
Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update
Prabhash, K. (2019) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_227_18 · Cited by 13
Improving Outcomes in Advanced Lung Cancer : Maintenance Therapy in Non-Small-Cell Lung Carcinoma = تحسين النتائج في سرطان الرئة المتقدم : العلاج المستدام في سرطان الرئة ذي الخلية غير الصغيرة
Furrukh, M., Burney, I. A., Kumar, S., Zahid, K. F., & Al-Moundhri, M. S. (2013) · Sultan Qaboos University medical journal · doi:10.12816/0003190 · Cited by 13
Axitinib for the treatment of advanced non-small-cell lung cancer
King, J. P., & Lee, S. M. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.775243 · Cited by 13
Maintenance Therapy for Advanced Lung Cancer: Who, What, and When?
Gerber, D. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5201 · Cited by 13
Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy
Yu, B., Lu, Y., Gao, F., Peng, J. P., Han, W., Zhang, P., Liu, G., Ru, N., Cui, G., Xu, X., et al. (2015) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s70679 · Cited by 13
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
Tsutani, Y., Miyata, Y., Masuda, T., Fujitaka, K., Doi, M., Awaya, Y., Kuyama, S., Kitaguchi, S., Ueda, K., Hattori, N., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-5146-3 · Cited by 13
Moving Programmed Death-1 Inhibitors to the Front Lines in Non–Small-Cell Lung Cancer
Gainor, J. F. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1205 · Cited by 13
50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic
Naidoo, J., Niroula, A., Uprety, D., Smeltzer, M. P., Geissen, N. M., Osarogiagbon, R. U., Mino-Kenudson, M. A., Yatabe, Y., Higgins, K. A., Desai, A. P., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.06.028 · Cited by 13
Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma
Jing, X., Zhou, L., Sun, X., Yu, J., & Meng, X. (2016) · Medicine · doi:10.1097/md.0000000000003351 · Cited by 12
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
Borget, I., Pérol, M., Pérol, D., Lavolé, A., Greillier, L., Dô, P., Westeel, V., Créquit, J., Léna, H., Monnet, I., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-953 · Cited by 12
Maintenance Treatment With Different Strategies in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Cai, H., Lin, Y., Li, W., & Li, X. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.10.010 · Cited by 12
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
Cardona, A. F., Rojas, L., Wills, B., Arrieta, O. G., Carranza, H., Vargas, C. A., Otero, J. M., Cuello, M., Corrales, L., Martin, C. M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154293 · Cited by 12
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non–Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care
Patel, J. D., Paz-Ares, L. G., Zinner, R., Barlési, F., Koustenis, A. G., & Obasaju, C. K. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.05.013 · Cited by 12
Self-citation
An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment
Caffo, O., Dipasquale, M., Murgia, V., Veccia, A., & Galligioni, E. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.804065 · Cited by 13
The results with the addition of metronomic cyclophosphamide to palliative radiotherapy for the treatment of non-small cell lung carcinoma.
Revannasiddaiah, S., Joshi, S. C., Pandey, K. C., Rastogi, M., Sharma, M., & Gupta, M. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.11.25 · Cited by 12
Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression
Chen, C., Chen, Y.-Y., Chen, J. J. W., Chen, K., Ho, C., Shih, J., Chang, Y., Yu, C., & Yang, P. (2017) · Oncotarget · doi:10.18632/oncotarget.18717 · Cited by 12
Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance
Lin, L., Zhao, J., Hu, J., Zou, G., Huang, F., Han, J., He, Y., & Cao, X. (2018) · Journal of Cancer · doi:10.7150/jca.24872 · Cited by 12
Integrative Omics Analysis Revealed that Metabolic Intervention Combined with Metronomic Chemotherapy Selectively Kills Cancer Cells
Shao, C., Lu, W., Wan, N., Wu, M., Bao, Q., Tian, Y., Lu, G., Wang, N., Hao, H., & Ye, H. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00138 · Cited by 12
High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study
Sumiyoshi, I., Okabe, T., Togo, S., Takagi, H., Motomura, H., Ochi, Y., Shimada, N., Haraguchi, M., Shibayama, R., Fujimoto, Y., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02761-1 · Cited by 12
Eligibility for Bevacizumab as an Independent Prognostic Factor for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study
Takagi, Y., Toriihara, A., Nakahara, Y., Yomota, M., Okuma, Y., Hosomi, Y., Shibuya, M., & Okamura, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059700 · Cited by 12
Non-Small-Cell Lung Cancer Treatment
Koyama, R., & Takahashi, K. (2016) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.62.7 · Cited by 12
Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non–Small-cell Lung Cancer
Gandara, D. R., Riess, J. W., Kelly, K. L., Li, T., Mack, P. C., & Lara, P. N. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.12.011 · Cited by 12
Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials
Huang, L., Cao, R., Wang, Y.-R., Sun, L., Zhang, X., Guo, Y., Zhao, J., Zhang, S., Jing, W., Song, J., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08136-5 · Cited by 11
Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study
Gu, X., Shi, Z., Shao, L., Zhang, Y., Zhang, Y., Song, Z., Wang, W., & Lou, G. (2022) · BMC Cancer · doi:10.1186/s12885-022-09674-2 · Cited by 11
Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Chen, C., Lin, J., Huang, J., Chen, K., Shih, J., Yu, C., & Yang, P. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.01.001 · Cited by 11
Maintenance or Consolidation Therapy for Non–Small-Cell Lung Cancer: A Meta-Analysis Involving 5841 Subjects
Zhang, C., Huang, C., Wang, J., Wang, X., & Li, K. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.01.002 · Cited by 11
Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
Riess, J. W., & Wakelee, H. A. (2012) · PubMed · Cited by 11
Treatment Satisfaction of Patients With Advanced Non–Small-cell Lung Cancer Receiving Platinum-based Chemotherapy: Results From a Prospective Cohort Study (PERSONAL)
Visser, S., de Mol, M., Cheung, K., van Toor, J. J., van Walree, N. C., Stricker, B. H. C., Oudsten, B. L. D., & Aerts, J. G. J. V. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.03.003 · Cited by 11
Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer
Chen, X., Zhou, F., Li, X., Yang, G., Zhao, C., Li, W., Wu, F., Yu, J., Gao, G., Li, J., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-19-4680 · Cited by 11
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR -mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer
Nishiyama, A., Katakami, N., Yoshioka, H., Iwasaku, M., Korogi, Y., Hata, A., Takeshita, J., Otsuka, K., Nishino, K., Uchida, J., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.017 · Cited by 13
Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study
Bylicki, O., Ferlay, C., CHOUAID, C., Lavolé, A., Barlési, F., Dubos, C., Westeel, V., Créquit, J., Corre, R., Vergnenégre, A., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828cb505 · Cited by 11
Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
Togashi, Y., Hayashi, H., Nakagawa, K., & Nishio, K. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s50358 · Cited by 11
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients
Kumar, R., Lu, S. K., Minchom, A. R., Sharp, A., Davidson, M., Gunapala, R., Yap, T. A., Bhosle, J., Popat, S., & O'Brien, M. E. R. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2950-1 · Cited by 10
Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients
Rothschild, S. I., Nachbur, R., Herzog, N., Passweg, J. R., & Pless, M. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100013 · Cited by 10
Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature
Russo, C. D., & Navarra, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.858354 · Cited by 11
De novo serine biosynthesis from glucose predicts sex-specific response to antifolates in non-small cell lung cancer cell lines
Sponagel, J., Devarakonda, S. H. K., Rubin, J. B., Luo, J. R., & Ippolito, J. E. (2022) · iScience · doi:10.1016/j.isci.2022.105339 · Cited by 12
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
Rittberg, R., Leung, B. O., Shokoohi, A., Pender, A., Wong, S. K., Al-Hashami, Z. S., Wang, Y., & Ho, C. (2023) · Current Oncology · doi:10.3390/curroncol30060402 · Cited by 10
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial
Postel-Vinay, S. C., Coves, J., Texier, M., Aldea, M. D., Gazzah, A., Dómine, M., Planchard, D., Peñas, R. D. L., González, M. A. S., Viteri, S., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02514-5 · Cited by 10
Beyond Adenocarcinoma: Current Treatments and Future Directions for Squamous, Small Cell, and Rare Lung Cancer Histologies
Gerber, D. E., Paik, P. K., & Dowlati, A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.147 · Cited by 10
Phase 2 study of S‐1 and carboplatin plus bevacizumab followed by maintenance S‐1 and bevacizumab for chemotherapy‐naive patients with advanced nonsquamous non–small cell lung cancer
Urata, Y., Okamoto, I., Takeda, M., Hattori, Y., Okuno, K., Shimada, T., Kurata, T., Kaneda, H., Miyazaki, M., Terashima, M., et al. (2013) · Cancer · doi:10.1002/cncr.28048 · Cited by 10
A potential new enriching trial design for selecting non‐small‐cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial
Lee, S. M., & Hackshaw, A. K. (2013) · Cancer Medicine · doi:10.1002/cam4.74 · Cited by 10
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Gautschi, O. P., Rothschild, S. I., Li, Q., Matter-Walstra, K. W., Zippelius, A., Betticher, D. C., Früh, M., Stahel, R. A., Cathomas, R. L., Rauch, D., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.11.007 · Cited by 10
Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
Cobo, M., Gutiérrez, V., Villatoro, R., Trigo, J. M., García, I. R., Lopez, O., Ruiz, M., Godoy-Ortíz, A., López, I., & Varela, M. A. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s118996 · Cited by 10
Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study
Slimano, F., Bozec, A. L., Cransac, A., Foucher, P., Lesauvage, F., Delclaux, B., Dory, A., Mennecier, B., Bertrand, B., Gubeno-Dumon, M.-C., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.02.007 · Cited by 10
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Maher, A. R., Miake-Lye, I. M., Beroes, J. M., & Shekelle, P. (2012) · Europe PMC (PubMed Central) · Cited by 10
The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients
Kucharczyk, T., Krawczyk, P. A., Powrózek, T., Kowalski, D. M., Ramlau, R., Kalinka‐Warzocha, E., Knetki‐Wróblewska, M., Winiarczyk, K., Krzakowski, M. J., & Milanowski, J. (2015) · Pathology & Oncology Research · doi:10.1007/s12253-015-9966-z · Cited by 10
Developments in pharmacotherapy for treating metastatic non-small cell lung cancer
Rossi, A., Sacco, P. C., Santabarbara, G., Sgambato, A., Casaluce, F., Palazzolo, G., Maione, P., & Gridelli, C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1280460 · Cited by 10
Self-citation
Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer
Miyahara, T., Sueoka‐Aragane, N., Iwanaga, K., Ureshino, N., Komiya, K., Nakamura, T., Nakashima, C., Abe, T., Matsunaga, H., & Kimura, S. H. (2017) · Medical Oncology · doi:10.1007/s12032-017-1053-8 · Cited by 10
Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer
Igawa, S., Sasaki, J., Otani, S., Shirasawa, M., Niwa, H., Kusuhara, S., Harada, S., Kubota, M., Katagiri, M., & Masuda, N. (2016) · Oncology · doi:10.1159/000446438 · Cited by 9
Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials
Qiao, L., Wang, J., Long, G., & Jiang, Y. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s128187 · Cited by 9
A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France
Taipale, K., Winfree, K. B., Boye, M. E., Basson, M., Sleilaty, G., Eaton, J., Evans, R., & CHOUAID, C. (2017) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s128371 · Cited by 9
Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid
Kwok, W. C., Cheong, T. F., Chiang, K. Y., Ho, J., Lam, D. C. L., Ip, M., & Tam, T. C. C. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.028 · Cited by 9
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
Kasai, T., Mori, K., Nakamura, Y., Seki, N., Ichikawa, Y., Saito, H., Kondo, T., Nishikawa, K., Otsu, S., Bessho, A., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6135 · Cited by 9
Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma
Hernández, A. S., Juan, Ó., Vidal-Martínez, J., Blanco, R., Maciá, S., Galiana, G. E., Aparisi, F., Noguera, J. G., Catot, S., Gaspà, F. L., et al. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1223-5 · Cited by 9
Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
Minami, S., & Kijima, T. (2015) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s73268 · Cited by 10
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy
Manegold, C., Adjei, A. A., Bussolino, F., Cappuzzo, F., Crinò, L., Dziadziuszko, R., Ettinger, D. S., Fennell, D. A., Kerr, K. M., Chevalier, T. L., et al. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000118 · Cited by 8
Self-citation
Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report
Dong, L., Xia, J., Zhang, J., Zhang, Y., Zhu, N., Zhang, P., Zhang, Y., Zhang, X., & Li, S. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0585-9 · Cited by 9
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non–small cell lung cancer: IFCT-1201 MODEL trial
Quoix, É., Audigier-Valette, C., Lavolé, A., Molinier, O., Westeel, V., Barlési, F., Treut, J. H. L., Pichon, É., Dauba, J., Otto, J., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.034 · Cited by 9
Self-citation
Expression of immune checkpoint PD‑1 in non‑small cell lung cancer is associated with tumor cell DNA‑dependent protein kinase
Saar, M., Narits, J., Mägi, L., Aaspõllu, H., Vapper, A., Kase, M., Minajeva, A., Vooder, T., Tamm, H., Buldakov, M., et al. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2369 · Cited by 9

Authors: Paz-Ares, L., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., Corral, J., Melemed, S., John, W., Chouaki, N., Zimmermann, A. H., Visseren-Grul, C., & Gridelli, C.
Affiliations: Instituto de Biomedicina de Sevilla (ES)
Institutul Oncologic Bucuresti (RO)
Heidelberg University (DE)
Centre Hospitalier Universitaire de Montpellier (FR)
Azienda Ospedaliera San Gerardo (IT)
Centre Hospitalier du Mans (FR)
Jawaharlal Nehru Cancer Hospital and Research Centre (IN)
University Medical Center Hamburg-Eppendorf (DE)
LungenClinic Grosshansdorf (DE)
Eli Lilly (United States) (US)
Azienda Ospedaliera S.Giuseppe Moscati (IT)
Corresponding author: Paz-Ares, Luis
ORCID: Paz-Ares, Luis
Dediu, Mircea
Thomas, Michael
Pujol, Jean-Louis
Molinier, Olivier
Reck, Martin
Gridelli, Cesare
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2012-03
Volume: 13
Issue: 3
Pages: 247-255
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(12)70063-3
OpenAlex: W2005244154
Cited by: 610
References: 33
Citations by year: 2026: 9 · 2025: 9 · 2024: 18 · 2023: 15 · 2022: 23 · 2021: 37 · 2020: 38 · 2019: 40 · 2018: 47 · 2017: 63 · 2016: 44 · 2015: 72 · 2014: 67 · 2013: 80 · 2012: 46
FWCI: 68.37
Type: journal article
Language: en
Open access: green
www.sciencedirect.com
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion, cc-by-nc-nd)
Funders: Eli Lilly and Company
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: maintenance therapy, non-squamous non-small cell lung cancer, cisplatin, induction chemotherapy, progression-free survival, best supportive care, disease progression, platinum-based doublets, first-line therapy, ECOG performance status, neutropenia, febrile neutropenia
MeSH terms: Pemetrexed, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Double-Blind Method, Drug Administration Schedule, Europe, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Placebos, Time Factors, Proportional Hazards Models, Treatment Outcome, Disease-Free Survival, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks